This clinical trial is focused on studying a condition known as Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH), which occurs due to Heart Failure with Preserved Ejection Fraction (HFpEF). This condition affects the blood vessels in the lungs and the heart’s ability to pump blood efficiently. The study will evaluate a treatment using a medication called sotatercept, which is administered as a solution for injection. Sotatercept is being compared to a placebo to understand its effects on this type of pulmonary hypertension.

The purpose of the study is to assess how effective and safe sotatercept is for people with Cpc-PH due to HFpEF. Participants in the study will receive either sotatercept or a placebo. The study will monitor changes in the participants’ health over time, focusing on how well their blood vessels function and their ability to walk a certain distance. The study will also keep track of any side effects or health changes that occur during the treatment period.

Participants will be involved in the study for a period of time, during which they will receive regular check-ups and assessments to monitor their condition and response to the treatment. The study aims to provide valuable information on whether sotatercept can be a beneficial treatment option for individuals with this specific type of pulmonary hypertension.